Convection Enhanced Delivery in the Setting of High-Grade Gliomas

Nwagwu, Chibueze D.; Immidisetti, Amanda; Jiang, Michael Y; Adeagbo, Oluwasegun; Adamson, David Cory; Carbonell, Anne-Marie

doi:10.3390/pharmaceutics13040561

Cited by 19 publications

(11 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration of free CpG in newly diagnosed or recurrent GBM patients failed to meet the endpoints. [ 8b,28 ] The development of minimally invasive approaches is critical to the success of adjuvant‐based immunotherapy for malignant glioma. To the best of our knowledge, t‐NanoCpG represents the first CpG nano‐immunoadjuvant that is reported to trigger strong anti‐glioma therapy via noninvasive administration.…”

Section: Resultsmentioning

confidence: 99%

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant

Wei

Zhao

et al. 2022

Advanced Science

View full text Add to dashboard Cite

Immunotherapy with toll like receptor 9 (TLR9) agonist CpG ODN offers an emergent strategy to treat life-threatening malignant glioma. CpG is typically applied invasively by intracranial and intrathecal administration which induces not only poor compliance and lessened potency but also possibly strong adverse effects and immunotoxicity. Here, it is reported that immunotherapy of murine LCPN glioma is greatly boosted by polymersome-steered intravenous and intranasal brain delivery of CpG. CpG is efficiently loaded in apolipoprotein E peptide-directed polymersomes to give blood-brain barrier permeable and glioma and cervical lymph node-homing CpG nano-immunoadjuvant (t-NanoCpG) which strongly stimulates the maturation of dendritic cells, antigen cross-presentation, and production of proinflammatory cytokines in vivo. Intriguingly, both intravenous and intranasal administration of t-NanoCpG brings about significant survival benefits in murine LCPN glioma-bearing mice while free CpG and nontargeted CpG nano-immunoadjuvant (NanoCpG) afford modest therapeutic effects. Moreover, combination of t-NanoCpG with radiotherapy further boosts the immunotherapeutic effects leading to more improved survival rate of mice. This intelligent brain-permeable nano-immunoadjuvant provides a new, minimally invasive and highly potent strategy for immunotherapy of glioma.

show abstract

Section: Resultsmentioning

confidence: 99%

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant

Wei

Zhao

et al. 2022

Advanced Science

View full text Add to dashboard Cite

show abstract

“…Strategies that have been employed for brain drug delivery include among others local drug delivery with convection-enhanced delivery, or drugloaded polymeric wafer implants. 254,255 However, due to their invasiveness, these methods exhibit a high chance of infection. Other methods include BBB disruption with osmotic agents or ultrasound, but these methods can potentially lead to neurotoxicity.…”

Section: Blood-brain Barriermentioning

confidence: 99%

Modulation of engineered nanomaterial interactions with organ barriers for enhanced drug transport

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Therefore, the safety and convenience of intra‐tumoral administration need to be further optimized. CED is a micro‐invasive technique that uses a catheter to establish a pressure gradient to locally deliver therapeutics into brain 243 . CED also can significantly limit systemic toxicity by directly delivering drugs to the site of cancer.…”

Section: Challenges In Oncolytic Virus Treating For Gliomamentioning

confidence: 99%

Oncolytic viral therapy as promising immunotherapy against glioma

Hu,

Tian,

et al. 2023

MedComm – Future Medicine

View full text Add to dashboard Cite

Glioma is a common primary central nervous system malignant tumor in clinical, traditional methods such as surgery and chemoradiotherapy are not effective in treatment. Therefore, more effective treatments need to be found. Oncolytic viruses (OVs) are a new type of immunotherapy that selectively infects and kills tumor cells instead of normal cells. OVs can mediate antitumor immune responses through a variety of mechanisms, and have the ability to activate antitumor immune responses, transform the tumor microenvironment from “cold” to “hot,” and enhance the efficacy of immune checkpoint inhibitors. Recently, a large number of preclinical and clinical studies have shown that OVs show great prospects in the treatment of gliomas. In this review, we summarize the current status of glioma therapies with a focus on OVs. First, this article introduces the current status of treatment of glioma and their respective shortcomings. Then, the important progress of OVs of in clinical trials of glioma is summarized. Finally, the urgent challenges of oncolytic virus treatment for glioma are sorted out, and related solutions are proposed. This review will help to further promote the use of OVs in the treatment of glioma.

show abstract

Convection Enhanced Delivery in the Setting of High-Grade Gliomas

Cited by 19 publications

References 91 publications

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant

Modulation of engineered nanomaterial interactions with organ barriers for enhanced drug transport

Oncolytic viral therapy as promising immunotherapy against glioma

Contact Info

Product

Resources

About